irs program accomplishments · form 990 part iii · fy2024
What they reported doing
- #1 primary $1.07BSEE SCHEDULE O
- #2 $257.99MSEE SCHEDULE O
named programs · 3 · from sources
What they call their work
Daraxonrasib Clinical Trials
Phase 3 clinical trials investigating daraxonrasib for metastatic pancreatic cancer, including trials comparing the drug to chemotherapy and studying its use in combination with other treatments.
David M. Rubenstein Center for Pancreatic Cancer Research
Comprehensive research and treatment program dedicated to advancing therapies for pancreatic cancer, including clinical and translational research.
Sloan Kettering Institute (SKI)
Basic biomedical research arm focused on understanding the biology of cancer through eight major research programs, fostering collaboration between scientists and clinicians.
activities · 6 groups
What they do
-
Comprehensive Cancer Care and Survivorship 4 activities
- Delivers high-volume clinical careProvides care during over one million outpatient visits annually, conducts more than 25,000 patient admissions, and issues over 200,000 pathology reports each year to support cancer diagnosis and staging.
- Operates a Multidisciplinary Brain Metastatic ClinicProvides coordinated care through a specialized clinic that integrates neurosurgery, radiation oncology, medical oncology, neuroradiology, neurology, and physiatry for patients with brain metastases, including telemedicine options.
- Operates inpatient and outpatient cancer care facilitiesManages a 26-story outpatient facility on Manhattan’s Upper East Side and an outpatient center in Uniondale, NY, along with 514 inpatient beds and a 72,000-square-foot surgical center to serve patients across New York.
- Provides personalized cancer care through multidisciplinary teamsDelivers expert, individualized care to patients of all ages using integrated teams of oncologists, surgeons, radiologists, pathologists, and psychiatrists, with treatment plans tailored to tumor characteristics and patient needs.
-
-
Biomedical Research and Innovation 2 activities
- Develops and tests FDA-approved cancer drugsHas developed 11 drugs approved by the US Food and Drug Administration through internal research and clinical development programs.
- Leads clinical trials for adult and pediatric cancersConducts over 1,800 clinical research protocols and leads more than 900 active clinical trials to improve treatment strategies for both adult and pediatric cancers, including phase 3 trials of targeted therapies like daraxonrasib for metastatic pancreatic cancer.
-
-
Cancer Research Funding 1 activity
- Conducts laboratory and translational cancer researchPerforms laboratory research to advance understanding of cancer biology and develop new therapies, including work on RAS-targeted treatments. This research underpins the development of novel cancer drugs and treatment strategies.
-
-
Organizational DEI Capacity Building 1 activity
- Promotes workplace inclusion through Employee Resource NetworksSupports diversity and inclusion via employee-formed task forces (ERNs) that foster supportive environments and amplify diverse perspectives within the organization.
-
-
Medical Professional Education & Training 1 activity
- Trains future scientists and cliniciansOffers mentorship, educational programs, and postdoctoral training for PhD, MD-PhD candidates, and emerging clinicians to build the next generation of cancer researchers and care providers.
-
-
Uncategorized 3 activities
- Disseminates clinical trial results and scientific findingsShares outcomes from clinical trials through peer-reviewed publications, such as in The New England Journal of Medicine, and presentations at major conferences like the American Society of Clinical Oncology Annual Meeting.
- Establishes standards in oncology nursing and educationAuthored the first comprehensive textbook on nursing oncology, setting foundational standards of care in the field.
- Offers specialized care for prostate cancerProvides timely consultations (within one week), advanced MRI imaging for accurate tumor assessment, and individualized treatment plans, including pre-surgical interventions to preserve sexual health.
-
financials · form 990 · fy2024
revenue
Total revenue$8.50B
Contributions & grants$834.08M10%
Program service revenue$7.07B83%
Investment income$466.32M5%
Other revenue$124.84M
expenses
Total expenses$7.91B
Program expenses99%
Admin / overhead0%
Fundraising1%
Salaries & benefits$3.98B
Grants paid out$25.49M
Largest expense lineCompensation
balance sheet
Total assets$15.47B
Cash$1.92B
Investments$6.60B
Liabilities$5.47B
Net assets$10.00B
Liquid reserves12.9 mo
4 years on record · 2020–2024 · YoY revenue +13.9%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 25
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| SELWYN VICKERS MD | Board member, President & CEO | 50 | $6.98M |
| JEFFREY DREBIN MD | CHAIRMAN ATTENDING | 50 | $2.91M |
| BABAK MEHRARA MD | CHIEF ATTENDING | 50 | $2.69M |
| MICHAEL HARRINGTON | EVP & CHIEF FINANCIAL OFFICER | 50 | $2.60M |
| BERNARD BOCHNER | ATTENDING, SURGERY | 50 | $2.46M |
| MICHELLE CORIDDI MD | ASSOCIATE ATTENDING, SURGERY | 50 | $2.40M |
| JASON KLEIN | SVP & CHIEF INVESTMENT OFFICER | 50 | $2.36M |
| JONAS NELSON MD | ASSOCIATE ATTENDING, SURGERY | 50 | $2.31M |
| LISA DEANGELIS MD | CHIEF PHYSICIAN EXECUTIVE | 50 | $2.30M |
| SHELLY ANDERSON | HOSPITAL PRESIDENT | 50 | $2.22M |
| JOAN MASSAGUE | CHIEF SCIENTIFIC OFFICER & DIRECTOR OF SKI | 50 | $2.17M |
| KENNETH MANOTTI | SVP & CHIEF DEVELOPMENT OFFICER | 50 | $2.15M |
| SIMON POWELL MD | CHAIRMAN ATTENDING | 50 | $1.97M |
| ERIN MCDONOUGH | EVP, MARKETING & COMMUNICATION OFFICER | 50 | $1.96M |
| JORGE LOPEZ ESQ | EVP & GENERAL COUNSEL | 50 | $1.75M |
| DEBRA BERNS | SVP & CHIEF RISK OFFICER | 50 | $1.72M |
| KATHRYN MARTIN | FORMER CHIEF OPERATING OFFICER | 0 | $1.70M |
| REMY EVARD | EVP, CHIEF DIGITAL OFFICER | 50 | $1.69M |
| LAKISHA MACK | EVP, CHIEF ADMINISTRATIVE OFFICER | 50 | $1.25M |
| TOMYA WATT | FORMER EVP, INTERIM CHIEF HUMAN RESOURCES OFFICER | 50 | $1.23M |
| ANAEZE OFFODILE MD | EVP, CHIEF STRATEGY OFFICER | 50 | $1.16M |
| TRACY GOSSELIN | SVP & Chief Nursing Executive | 50 | $1.06M |
| CRAIG THOMPSON MD | FORMER PRESIDENT & CEO | 50 | $991K |
| MARK SVENNINGSON | FORMER VP, FINANCE | 0 | $800K |
| FREDRICK GROVES | FORMER EVP HOSPITAL ADMINISTRATION | 0 | $711K |
relationships · 16
Who they work with
- Alpha Phi Alpha Fraternity, Inc. Partner — Collaborates with the fraternity on prostate cancer awareness drives in the Black community.
- American College of Surgeons Government — MSK is accredited by the Commission on Cancer, a quality program of the American College of Surgeons.
- American Nurses Credentialing Center Government — MSK is recognized by the ANCC Magnet Recognition Program for nursing excellence.
- American Society of Clinical Oncology Network — Presented clinical trial results at the ASCO Annual Meeting
- Dr. Brandon Imber Partner — Radiation oncologist at MSK who contributes to treatment planning and patient counseling for brain metastases.
- Dr. Joshua Budhu Partner — Neurologist and neuro-oncologist at MSK who specializes in managing brain metastases and integrating quality-of-life considerations into care.
- Dr. Nelson Moss Partner — Neurosurgeon at MSK involved in treating brain metastases and developing surgical approaches including laser ablation.
- Employee Resource Networks Partner — Voluntary, employee-formed task forces organized around dimensions of diversity to support inclusion at MSK.
- Human Oncology and Pathogenesis Program Partner — Physician-scientist program within Memorial Hospital translating molecular insights into new cancer treatments.
- Revolution Medicine Partner — Collaborated on the clinical development and funding of daraxonrasib
- Sloan Kettering Institute Partner — Research arm focused on fundamental biomedical research, integrated with Memorial Hospital since 1980.
- The Joint Commission Government — MSK has achieved accreditation from The Joint Commission for healthcare quality and safety.
- The New England Journal of Medicine Network — Published clinical trial findings in the journal
- The Rockefeller University Partner — Collaborates on PhD and MD/PhD programs in biomedical sciences
- U.S. Food and Drug Administration Government — Received Breakthrough Therapy designation and regulatory review for daraxonrasib
- Weill Cornell Medical College Partner — Collaborates on PhD and MD/PhD programs and provides clinical training for residents and medical students
strategies · 4
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Integrated Bench-to-Bedside Researchmethodology: bench_to_bedsideBy integrating basic, translational, and clinical research, MSK accelerates the application of scientific discoveries to patient care because close collaboration between laboratory and clinical scientists shortens the path from discovery to treatment.
- Multidisciplinary Team Care for Personalized Treatmentmethodology: multidisciplinary_care_teamsBy convening specialists from multiple disciplines into unified care teams, MSK develops individualized treatment plans that improve clinical decision-making and patient understanding because diverse expertise is systematically integrated into each patient’s care pathway.
- Patient-Centered Decision-Making Balancing Outcomes and Quality of Lifemethodology: patient_centered_decision_makingBy incorporating patient priorities and quality-of-life considerations into treatment planning, MSK ensures that clinical decisions reflect individual values and goals, leading to more sustainable and personally meaningful outcomes, especially in complex cases like brain metastases.
- Targeted Research on Previously Undruggable Mutationsmethodology: long_term_targeted_research_on_undruggable_mutationsBy focusing long-term research efforts on historically undruggable targets like RAS mutations, MSK advances therapies for intractable cancers, because sustained, mechanism-driven investigation enables breakthroughs where conventional approaches have failed.